China Pharma Holdings, Inc. Reports Second Quarter 2020 Financial Results

Rhea-AI Summary

China Pharma Holdings, Inc. (CPHI) reported a 46.8% revenue increase to $3.8 million for Q2 2020, driven primarily by a one-time sale of COVID-19 testers contributing $1.7 million. Gross margin improved to 30.5% from 6.4% year-over-year, while the company achieved an operating income of $0.1 million, compared to a loss of $0.8 million in the same quarter of 2019. Despite positive growth, net income was minimal at $0.01 million, as prior drug sales were affected by the COVID-19 outbreak. Cash and equivalents stood at $1.8 million, up from $1.1 million.

Positive

• Revenue increased by 46.8% to $3.8 million in Q2 2020.
• Gross margin improved to 30.5% from 6.4% in Q2 2019.
• Operating income of $0.1 million in Q2 2020, compared to a loss of $0.8 million in Q2 2019.
• Cash and cash equivalents increased to $1.8 million as of June 30, 2020.

Negative

• Net income was minimal at $0.01 million, down from a net loss of $0.84 million in Q2 2019.
• Ongoing sales challenges for pharmaceutical products due to COVID-19 fears.

HAIKOU CITY, China, Aug. 14, 2020 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended June 30, 2020.

Second Quarter Highlights

• Revenue increased 46.8% to $3.8 million in the second quarter 2020 from $2.6 million in the same period of 2019;
• Gross margin was 30.5% in the second quarter 2020, compared to 6.4% in the same period of 2019;
• Income from operations was $0.1 million in the second quarter 2020 compared to loss from operations of $0.8 million in the same period of 2019, an improvement of approximately $0.8 million;
• Net income was $0.01 million in the second quarter 2020 compared to net loss of $0.84 million in the same period of 2019.  Earnings per common stock was $0.00 per basic and diluted share in the second quarter 2020, as compared to loss per common stock of $0.02 per basic and diluted share in the second quarter of 2019.
• We completed a foreign trade of COVID-19 testers in the second quarter of 2020. This one-time business contributed approximately $1.7 million to our revenue for the three months ended June 30, 2020.

Ms. Zhilin Li, China Pharma's Chairman and CEO, commented, "The COVID-19 outbreak continued to have a substantial negative impact on our sales of pharmaceutical products. Many people try to avoid going to the hospital for fear of cross-contamination or potential infection. However, the majority of our existing products are prescription drugs. The macro-environment has negatively impacted our drug sales in this period. Fortunately, we completed a one-time foreign trade business this quarter. Due to the continued spread of COVID-19 in the international community, COVID-19 testers have become an urgently needed product in many markets. We have actively leveraged market information as well as our expertise to complete the order in an efficient manner." Ms. Li continued, "along with the lasting efforts to place emphasis on the marketing and sales of our current exiting pharmaceutical products, we continue to explore in the field of comprehensive healthcare. Comprehensive healthcare focuses on people's daily life, aging and disease and pays attention to all kinds of risk factors and misunderstandings affecting health. We aim to leverage our expertise in the PRC for the development, manufacture and commercialization of pharmaceutical and comprehensive healthcare products for the benefit of human health."

Second Quarter Results

Revenue increased by 46.8% to $3.8 million for the three months ended June 30, 2020, as compared to $2.6 million for the three months ended June 30, 2019. This increase was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020. Because of the market demand for COVID-19 related products, we received an export order for diagnostic test, which we purchased from a third party. This one-time business contributed approximately $1.7 million to our revenue for the three months ended June 30, 2020. This is a milestone of our continuous efforts to explore various niche markets, products and regions based on our experiences and abilities.

For the three months ended June 30, 2020, our cost of revenue was $2.6 million, or 70% of total revenue, comparing to $2.4 million, or 94% of total revenue, for the same period in 2019. The decrease in cost of revenue was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020.

Gross profit for the three months ended June 30, 2020 was $1.1 million, as compared to $0.2 million during the same period in 2019. Our gross profit margin in the three months ended June 30, 2020 was 30.5% as compared to 6.4% during the same period in 2019. The increase in our gross profit margin was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020.

Our selling expenses for the three months ended June 30, 2020 and 2019 were $0.7 million and $0.5 million, respectively. Selling expenses accounted for 19.3% of the total revenue in the three months ended June 30, 2020, as compared to 19.7% during the same period in 2019. Because of adjustments in our sales practices, and reform of healthcare policies, we reduced number of personnel and expenses to efficiently support our sales and the collection of accounts receivable.

Our general and administrative expenses were both $0.3 million for the three months ended June 30, 2020 and 2019, respectively. General and administrative expenses accounted for 8.6% and 13.0% of our total revenues in the three months ended June 30, 2020 and 2019, respectively.

Our operating income for the three months ended June 30, 2020 was $0.1 million, compared to an operating loss of $0.8 million during the same period in 2019.

Net income for the three months ended June 30, 2020 was $0.01 million, or $0.00 per basic and diluted common share, as compared to net loss of $0.84 million, or $0.02 per basic and diluted common share for the same period a year ago. The decrease in net loss was mainly the result of a foreign trade of COVID-19 testers we completed in the second quarter of 2020.

Six Months Results

Revenue was both $5.5 million for the six months ended June 30, 2020 and 2019, respectively. The first three months in this year was impacted by COVID-19 outbreak in China, however there was one-time revenue from the selling of COVID-19 testers around $1.7 million, leading the revenue back to prior year performance.

Gross profit for the six months ended June 30, 2020 was $1.3 million, compared to $0.8 million in the same period in 2019. Our gross profit margin in the six months ended June 30, 2020 was 24.3% compared to 14.9% in the same period in 2019. The increase in our gross profit margin was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020.

Net loss for the six months ended June 30, 2020 was $0.6 million, as compared to net loss of $1.3 million for the six months ended June 30, 2019. The decrease of net loss was mainly due to a foreign trade of COVID-19 testers we completed in the second quarter of 2020. 

Financial Condition

As of June 30, 2020, the Company had cash and cash equivalents of $1.8 million compared to $1.1 million as of December 31, 2019.

Our net accounts receivable was both $0.6 million as of June 30, 2020 and December 31, 2019, respectively.

For the six months ended June 30, 2020, cash flow used in operating activities was $0.2 million, as compared to cash flow provided by operating activities of $0.2 million for the same period in 2019.

Conference Call

The Company will hold a conference call at 8:30 am E.T. on August 14, 2020 to discuss the results of the second quarter of 2020. Listeners may access the call by registering via the link below:

http://apac.directeventreg.com/registration/event/7427437  

A replay of the call will be accessible through August 22, 2020 by dialing 1-855-452-5696 or 61-281-990-299 for international callers, Conference ID # 7427437.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnique Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.

- FINANCIAL TABLES FOLLOW -

 

 

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
		June 30,		December 31,
		2020		2019
ASSETS
Current Assets:
Cash and cash equivalents		$      1,813,544		$      1,074,979
Restricted cash		222,996		109,908
Banker's acceptances		11,251		45,756
Trade accounts receivable, less allowance for doubtful
accounts of $17,342,097 and $17,575,100, respectively		595,733		635,371
Other receivables, less allowance for doubtful
accounts of $23,715 and $22,729, respectively		86,065		46,643
Advances to suppliers		277,900		404
Inventory		3,852,972		3,588,824
Prepaid expenses		397,374		77,120
Total Current Assets		7,257,835		5,579,005
Property, plant and equipment, net		15,631,653		16,313,827
Operating lease right of use asset		90,289		136,779
Intangible assets, net		185,244		205,611
TOTAL ASSETS		$    23,165,021		$    22,235,222
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Trade accounts payable		$      1,025,098		$      1,366,330
Accrued expenses		180,719		189,880
Other payables		3,753,356		3,560,332
Advances from customers		592,961		505,398
Other payables - related parties		2,152,161		2,071,986
Operating lease liability, current portion		93,510		91,306
Current portion of construction loan facility		2,118,794		2,150,168
Current portion of lines of credit		1,200,650		-
Bankers' acceptance notes payable		222,996		109,908
Total Current Liabilities		11,340,245		10,045,308
Non-current Liabilities:
Construction loan facility		1,977,541		2,150,168
Lines of credit, net of current portion		706,264		-
Operating lease liability, net of current portion		-		48,701
Deferred tax liability		742,450		753,444
Total Liabilities		14,766,500		12,997,621
Commitments and Contingencies (Note 14)
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized;
no shares issued or outstanding		-		-
Common stock, $0.001 par value; 95,000,000 shares authorized;
43,579,557 shares and 43,579,557 shares outstanding, respectively		43,580		43,580
Additional paid-in capital		23,590,204		23,590,204
Accumulated deficit		(26,620,246)		(25,972,402)
Accumulated other comprehensive income		11,384,983		11,576,219
Total Stockholders' Equity		8,398,521		9,237,601
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		$    23,165,021		$    22,235,222

 

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)
		For the Three Months				For the Six Months
		Ended June 30,				Ended June 30,
		2020		2019		2020		2019
Revenue		$         3,770,723		$         2,569,408		$         5,534,678		$         5,498,681
Cost of revenue		2,620,925		2,405,860		4,190,441		4,678,603
Gross profit		1,149,798		163,548		1,344,237		820,078
Operating expenses:
Selling expenses		727,642		505,866		1,053,737		984,557
General and administrative expenses		322,445		334,550		711,004		763,367
Research and development expenses		30,044		66,008		78,863		135,926
Bad debt (benefit) expense		(5,318)		10,092		24,928		23,404
Total operating expenses		1,074,813		916,516		1,868,532		1,907,254
Income (loss) from operations		74,985		(752,968)		(524,295)		(1,087,176)
Other income (expense):
Interest income		1,212		12,119		1,598		15,376
Interest expense		(63,144)		(97,254)		(125,147)		(184,034)
Net other expense		(61,932)		(85,135)		(123,549)		(168,658)
Income (loss) before income taxes		13,053		(838,103)		(647,844)		(1,255,834)
Income tax  expense		-		-		-		-
Net income (loss)		13,053		(838,103)		(647,844)		(1,255,834)
Other comprehensive income - foreign currency
translation adjustment		5,796		(811,164)		(191,236)		24,701
Comprehensive income (loss)		$              18,849		$        (1,649,267)		$           (839,080)		$        (1,231,133)
Earnings (loss) per share:
Basic and diluted		$                  0.00		$                 (0.02)		$                 (0.01)		$                 (0.03)
Weighted average shares outstanding		43,579,557		43,579,557		43,579,557		43,579,557

 

 

 

CHINA PHARMA HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
		For the Six Months
		Ended June 30,
		2020		2019
Cash Flows from Operating Activities:
Net loss		$        (647,844)		$     (1,255,834)
Depreciation and amortization		1,305,070		1,575,870
Bad debt expense		24,928		23,404
Inventory write off		-		111,533
Changes in assets and liabilities:
Trade accounts and other receivables		(305,183)		(284,126)
Advances to suppliers		(279,380)		(10,615)
Inventory		(14,136)		960,946
Trade accounts payable		(323,470)		223,562
Accrued taxes payable		279,748		(43,632)
Other payables and accrued expenses		(79,967)		(369,547)
Change in bankers' acceptance notes payable		115,468		(781,626)
Advances from customers		95,579		31,548
Prepaid expenses		(323,553)		(31,309)
Net Cash (Used in) Provided by Operating Activities		(152,740)		150,174
Cash Flows from Investing Activities:
Purchases of property and equipment		(840,449)		(73,538)
Net Cash Used in Investing Activities		(840,449)		(73,538)
Cash Flows from Financing Activities:
Proceeds from lines of credit		1,919,818		-
Payments of construction term loan		(142,209)		(147,475)
Proceeds (payments) of related party payables		90,551		(231,252)
Net Cash Provided by) Used in Financing Activities		1,868,160		(378,727)
Effect of Exchange Rate Changes on Cash		(23,318)		768
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash		851,653		(301,323)
Cash, Cash Equivalents and Restricted Cash at Beginning of Period		1,184,887		2,460,527
Cash, Cash Equivalents and Restricted Cash at End of Period		$       2,036,540		$       2,159,204
Cash and Cash Equivalents		1,813,544		1,655,892
Restricted cash		222,996		503,312
Cash, Cash Equivalents and Restricted Cash at End of Period		$       2,036,540		$       2,159,204
Supplemental Cash Flow Information:
Cash paid for income taxes		$                    -		$                    -
Cash paid for interest		$          118,374		$          178,991
Supplemental Noncash Investing and Financing Activities:
Issuance of banker's acceptances		$                    -		$                    -
Accounts receivable collected with banker's acceptances		270,453		378,585
Inventory purchased with banker's acceptances		304,520		399,455
Right-of-use assets obtained in exchange for operating lease obligations		-		233,629

 

View original content:http://www.prnewswire.com/news-releases/china-pharma-holdings-inc-reports-second-quarter-2020-financial-results-301112379.html

SOURCE China Pharma Holdings, Inc.

FAQ

What were the financial results of CPHI for Q2 2020?

CPHI reported a revenue of $3.8 million for Q2 2020, a 46.8% increase from the previous year.

How did COVID-19 impact China Pharma's sales?

The outbreak negatively impacted drug sales, but a one-time trade of COVID-19 testers contributed $1.7 million.

What is the gross profit margin for CPHI in Q2 2020?

The gross profit margin was 30.5% for Q2 2020, significantly improved from 6.4% in Q2 2019.

What were CPHI's net income figures for the second quarter?

Net income was $0.01 million for Q2 2020, compared to a net loss of $0.84 million in Q2 2019.